PharmaMar (MSE:PHM) has signed a Memorandum of Understanding with the Research Center for Oceanography, the Indonesian Institute of Science (RCO-LIPI), in the presence of the Indonesian Ambassador in Spain, H.E. Mr. Drs. Hermono, M.A.. The aim of this collaboration is to develop a research program that allows the study of the Indonesian marine biodiversity as a source of new antitumor compounds.
Under the terms of this agreement the foundations are laid, through which PharmaMar and the RCO-LIPI can work together in the collection of marine invertebrates, in the isolating of new marine bacteria and in the identification of new antitumor compounds. This collaboration will also permit the exchange of knowledge between the two institutions.
In the words of Mr. José María Fernández, President of PharmaMar, "for us, investing in R&D is crucial for the advancement of science, and the Memorandum with the Indonesian Research Center for Oceanography is a clear example of this," adding, "we are sure that this alliance will reinforce our mission and commitment in the research against cancer, to enable us to respond to unmet medical needs, even more.".
Dr. Dirhamsyah, MA, Director of Research of the RCO - LIPI, has explained that "we are proud to sign this agreement with PharmaMar as it allows us both to work together in the development of cutting-edge technology."
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin, plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.
This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.